Talk:Dacomitinib

Improved PFS in NSCLC - ASCO 2017
Could mention [https://www.medpagetoday.com/MeetingCoverage/ASCO/65818 Dacomitinib Sets PFS Record in Phase III NSCLC Trial. 2017] : "...Dacomitinib treatment extended median progression-free survival by 5.5 months versus gefitinib -- to 14.7 months -..." & toxicity issues - Rod57 (talk) 10:05, 9 June 2017 (UTC)

Clarify inhibitory effect on normal and various mutated forms of EGFR
The trials seem to be on patients with mutated EGFR but does it also inhibit normal EGFR ? - Rod57 (talk) 10:17, 9 June 2017 (UTC)